Exogenous GLP-1 receptor agonists, including exenatide, liraglutide, and semaglutide, function by mimicking the incretin hormone, GLP-1, to stimulate insulin secretion in T2DM, where endogenous incretin function and insulin sensitivity are impaired. This evidence concerns the gene GCG and type 2 diabetes mellitus.